IL-6 multivariate analysis of Checkmate-066 and -067
| CheckMate -066a | CheckMate -067b | |||||||||
| NIVO | DTIC | NIVO | NIVO+IPI | IPI | ||||||
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| IL-6, LLOQ ≥vs < | 1.58 (0.977 to 2.578) | 0.061 | 1.39 (0.864 to 2.257) | 0.17 | 2.54 (1.31 to 4.92) | 0.0058 | 2.07 (1.15 to 3.71) | 0.015 | 3.9 (2.38 to 6.41) | 7.71E−08 |
| LDH, ULN>vs ≤ | 1.87 (1.22 to 2.87) | 0.004 | 1.92 (1.30 to 2.83) | 9.58E−04 | 1.52 (1.05 to 2.20) | 0.026 | 1.66 (1.15 to 2.38) | 0.0067 | 1.63 (1.21 to 2.20) | 0.0011 |
| ECOG, 1 vs 0 | 1.4 (0.895 to 2.190) | 0.14 | 1.23 (0.86 to 1.77) | 0.25 | 1.4 (0.971 to 2.042) | 0.071 | 1.82 (1.26 to 2.63) | 0.0013 | 1.48 (1.09 to 2.02) | 0.012 |
| M stage, M1c vs M0/M1a/M1b | 0.96 (0.630 to 1.487) | 0.88 | 1.4 (0.972 to 2.017) | 0.071 | 1.7 (1.18 to 2.44) | 0.0039 | 1.49 (1.02 to 2.18) | 0.041 | 1.57 (1.16 to 2.11) | 0.0033 |
| BRAF status, mutated vs wildtype | – | – | – | – | 0.76 (0.525 to 1.104) | 0.15 | 0.73 (0.499 to 1.093) | 0.13 | 0.8 (0.594 to 1.104) | 0.18 |
| N/L ratio | 1.11 (1.05 to 1.16) | 1.27E−04 | 1.13 (1.08 to 1.19) | 1.49E−06 | 1.02 (0.987 to 1.056) | 0.23 | 1.06 (1.01 to 1.11) | 0.017 | 1.01 (0.998 to 1.035) | 0.076 |
DTIC, dacarbazine; IL, interleukin; IPI, ipilimumab; LLOQ, lower limit of quantification; M, metastases; NIVO, nivolumab; N/L, neutrophil/lymphocyte; ULN, Upper limit of normal.